Pregnancy in XXXX : a prospective study.

@entity1 @entity1276 @entity229 @entity117 @entity1252 @entity1988 @entity1468 @entity1011 @entity5617
The objective of this work was to analyse the course of maternal disease and fetal outcome in pregnant @entity1 with @entity1252 ( @entity1252 ) counselled and followed according to a protocol intended to optimize maternal and fetal outcome. The prospective study included all pregnancies between 1987 and 1993 in @entity1252 @entity1 known at least 6 months before pregnancy at the Lupus Clinic of our hospital. In 25 @entity1 there were 35 pregnancies. Thirty-four (97%) started at sustained remission of disease; 11 (31%) were in women with antiphospholipid antibodies (aPL); 14 (40%) in @entity1 with a history of biopsy-proven @entity1988 ; one (3% in a @entity1 with a serum @entity1011 above 125 mumol/l. In 29 pregnancies (82%) maternal disease remained inactive during gestation. In three pregnancies (9%) active disease was treated with @entity229 . There were no serious post-partum flares of disease. Pregnancy resulted in 25 (71%) live births, 8 (23%) first trimester abortions, and one @entity5617 . One pregnancy was terminated because of @entity1276 . Nine of 25 (36%) live births were delivered by caesarean section. For 6 of 9 (67%) caesarean sections the indication was fetal distress and @entity1468 . In the majority of @entity1 with @entity1252 who conceive at remission, the disease does not flare in pregnancy. With optimal obstetric care, close follow-up and treatment with low-dose @entity117 if aPL are present, a high success rate (71%) can be achieved.
